IceCure Medical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	3.26	3.23	3.09	4.14	3.87	1.63
Revenue Growth (YoY)	7.02%	4.67%	-25.45%	6.98%	137.74%	-
Cost of Revenue	2.01	1.93	1.64	1.94	1.42	1.1
Gross Profit	1.25	1.3	1.45	2.2	2.44	0.52
Selling, General & Admin	8.41	8.6	9.06	6.04	2.78	2.31
Research & Development	8.11	8.27	9.12	5.88	3.81	3
Operating Expenses	16.52	16.88	18.18	11.92	6.59	5.31
Operating Income	-15.27	-15.58	-16.74	-9.72	-4.14	-4.78
Interest Expense / Income	-0.78	-0.92	0.24	0.17	-0.41	-0.23
Pretax Income	-14.49	-14.65	-16.98	-9.9	-3.73	-4.55
Net Income	-14.49	-14.65	-16.98	-9.9	-3.73	-4.55
Shares Outstanding (Basic)	47	46	37	29	17	14
Shares Outstanding (Diluted)	47	46	37	29	17	14
Shares Change	2.44%	23.29%	29.66%	66.67%	25.75%	-
EPS (Basic)	-0.32	-0.32	-0.46	-0.35	-0.22	-0.33
EPS (Diluted)	-0.32	-0.32	-0.46	-0.35	-0.22	-0.33
Free Cash Flow	-12.69	-13	-15.18	-13.14	-3.91	-2.09
Free Cash Flow Per Share	-0.27	-0.28	-0.41	-0.46	-0.23	-0.15
Gross Margin	38.29%	40.26%	46.84%	53.04%	63.19%	32.21%
Operating Margin	-468.09%	-482.38%	-542.59%	-234.99%	-107.08%	-294.04%
Profit Margin	-444.30%	-453.76%	-550.34%	-239.13%	-96.43%	-279.72%
Free Cash Flow Margin	-389.15%	-402.63%	-492.16%	-317.50%	-101.16%	-128.58%
EBITDA	-14.94	-15.25	-16.49	-9.6	-4.08	-4.75
EBITDA Margin	-458.00%	-472.38%	-534.55%	-231.92%	-105.46%	-292.07%
Depreciation & Amortization	0.33	0.32	0.25	0.13	0.06	0.03
EBIT	-15.27	-15.58	-16.74	-9.72	-4.14	-4.78
EBIT Margin	-468.09%	-482.38%	-542.59%	-234.99%	-107.08%	-294.04%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).